Gyo Asai

1.1k total citations
11 papers, 279 citations indexed

About

Gyo Asai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gyo Asai has authored 11 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Gyo Asai's work include Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Gyo Asai is often cited by papers focused on Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Gyo Asai collaborates with scholars based in Japan. Gyo Asai's co-authors include Kaoru Shimokata, Yukio Ando, Hideo Saka, Shigeki Sugiura, Tetsuya Kamataki, Nobuyuki Yamamoto, Naruo Yoshimura, Minoru Takada, S. Kudoh and Masahiro Fukuoka and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancer Science.

In The Last Decade

Gyo Asai

11 papers receiving 276 citations

Peers

Gyo Asai

ONCOL

MB

PPCH

PRM

EPIDE

Miguel A. Villalona United States

J A Sinkule United States

Chirag G. Patel United States

Yusuke Hara Japan

Carin A.T.C. Lunenburg Netherlands

Sushma Thomas United States

Dion Chen United States

F. J. Suchy United States

Chitra Saran United States

Kathy Harry United States

Miguel A. Villalona United States

Gyo Asai

191 ×1.1

ONCOL

191 ×1.2

MB

51 ×0.8

PPCH

37 ×0.6

PRM

25 ×0.5

EPIDE

Citations per year, relative to Gyo Asai Gyo Asai (= 1×) peers Miguel A. Villalona

Countries citing papers authored by Gyo Asai

Since Specialization

Citations

This map shows the geographic impact of Gyo Asai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gyo Asai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gyo Asai more than expected).

Fields of papers citing papers by Gyo Asai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gyo Asai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gyo Asai. The network helps show where Gyo Asai may publish in the future.

Co-authorship network of co-authors of Gyo Asai

This figure shows the co-authorship network connecting the top 25 collaborators of Gyo Asai. A scholar is included among the top collaborators of Gyo Asai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gyo Asai. Gyo Asai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Tanaka, Shigeru, et al.. (2019). Antitumor effect of immune checkpoint inhibitor for subsequent therapy. Annals of Oncology. 30. vi135–vi135. 1 indexed citations

2.

Ando, Masahiko, Yukiko Nakamura, Haruyasu Murakami, et al.. (2006). Influence of histological type, smoking history and chemotherapy on survival after first‐line therapy in patients with advanced non‐small cell lung cancer. Cancer Science. 98(2). 226–230. 30 indexed citations

3.

Asai, Gyo, Nobuyuki Yamamoto, Takayasu Kurata, et al.. (2006). Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer. Journal of Thoracic Oncology. 1(3). 226–230. 4 indexed citations

4.

Yamamoto, Nobuyuki, Junji Tsurutani, Naruo Yoshimura, et al.. (2006). Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.. PubMed. 26(1B). 777–81. 55 indexed citations

5.

Ohde, Yasuhisa, Kei Nakagawa, Takehiro Okumura, et al.. (2005). P-377 Evaluation of adrenal masses in patients with non-small cell lung cancer using 18F-fluorodeoxyglucose positron emission tomography. Lung Cancer. 49. S214–S214. 1 indexed citations

6.

Takahashi, Toshiaki, et al.. (2004). Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7282–7282. 5 indexed citations

7.

Ueda, Shinya, et al.. (2004). Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7282–7282. 2 indexed citations

8.

Asai, Gyo, Nobuyuki Yamamoto, Masakazu Toi, et al.. (2002). Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer. Cancer Chemotherapy and Pharmacology. 49(6). 468–472. 13 indexed citations

9.

Asai, Gyo & M. Fukuoka. (1999). [Phase II studies of gemcitabine for non-small cell lung cancer in Japan].. PubMed. 26(7). 884–9. 1 indexed citations

10.

Ando, Yukio, Hideo Saka, Gyo Asai, et al.. (1998). UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Annals of Oncology. 9(8). 845–847. 158 indexed citations

11.

Asai, Gyo, Yukio Ando, Hideo Saka, et al.. (1998). Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model. European Journal of Clinical Pharmacology. 54(9-10). 725–727. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact